- Home
- CHRS vs NKSH Comparison
CHRS vs NKSH Comparison
Compare CHRS & NKSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- NKSH
- Stock Information
- Founded
- CHRS 2010
- NKSH 1891
- Country
- CHRS United States
- NKSH United States
- Employees
- CHRS N/A
- NKSH N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- NKSH Major Banks
- Sector
- CHRS Health Care
- NKSH Finance
- Exchange
- CHRS Nasdaq
- NKSH Nasdaq
- Market Cap
- CHRS 191.3M
- NKSH 185.4M
- IPO Year
- CHRS 2014
- NKSH N/A
- Fundamental
- Price
- CHRS $1.37
- NKSH $30.14
- Analyst Decision
- CHRS Strong Buy
- NKSH Strong Buy
- Analyst Count
- CHRS 4
- NKSH 1
- Target Price
- CHRS $5.38
- NKSH $38.00
- AVG Volume (30 Days)
- CHRS 2.0M
- NKSH 14.2K
- Earning Date
- CHRS 03-12-2025
- NKSH 10-24-2024
- Dividend Yield
- CHRS N/A
- NKSH 5.18%
- EPS Growth
- CHRS N/A
- NKSH N/A
- EPS
- CHRS N/A
- NKSH 1.44
- Revenue
- CHRS $304,340,000.00
- NKSH $43,450,000.00
- Revenue This Year
- CHRS $2.47
- NKSH N/A
- Revenue Next Year
- CHRS N/A
- NKSH $19.72
- P/E Ratio
- CHRS N/A
- NKSH $20.17
- Revenue Growth
- CHRS 44.19
- NKSH N/A
- 52 Week Low
- CHRS $0.66
- NKSH $26.00
- 52 Week High
- CHRS $2.87
- NKSH $35.00
- Technical
- Relative Strength Index (RSI)
- CHRS 49.80
- NKSH 55.40
- Support Level
- CHRS $1.31
- NKSH $26.00
- Resistance Level
- CHRS $1.60
- NKSH $30.68
- Average True Range (ATR)
- CHRS 0.12
- NKSH 0.95
- MACD
- CHRS -0.03
- NKSH 0.33
- Stochastic Oscillator
- CHRS 28.00
- NKSH 86.32
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About NKSH National Bankshares Inc.
National Bankshares Inc is a bank holding company. It focuses on lending to small and mid-sized businesses and individuals. The types of loans it offers include commercial and agricultural, commercial real estate, construction for commercial and residential properties, residential real estate, home equity, and various consumer loan products. It also operates an insurance and brokerage subsidiary, National Bankshares Financial Services, Inc. The company earns its revenues from interest and fees on loans, non-interest income, and investments.